Oral Menopausal Therapy Linked to Higher Stroke Risk
A study found women taking certain oral hormones faced higher odds of stroke and other vascular conditions.
Updated on Oct. 9, 2026 in Stroke
Live Poll
Does this study make you less confident in the safety of your current hormone therapy?
A nested case-control study published in The BMJ on September 23, 2026, found that oral menopausal hormone therapy was associated with an increased risk of venous thromboembolism, ischemic stroke, and myocardial infarction. The findings highlight potential vascular safety concerns for women aged 50 to 69 using these medications.
Why it matters
These findings provide essential data for women weighing the benefits of hormone therapy against cardiovascular safety concerns. The research helps clarify how different delivery methods and dosages might influence individual risk profiles for clotting and heart events.
In a nested case-control study of over 40,000 women aged 50 to 69, researchers matched patients with specific thrombotic events to controls. The study found hazard ratios up to 1.6 for venous thromboembolism among oral estrogen users, while noting that transdermal therapy largely showed no such association.
The players
The BMJ
A prominent peer-reviewed medical journal that publishes original research across various health disciplines.
HealthDay
A health-focused news wire service that reports on clinical research and public health developments.
The details
The study suggests that oral hormone therapy may influence vascular health differently depending on the dosage and delivery method used. Researchers observed that oral estradiol doses exceeding 1 mg daily for more than one year were linked to higher risks, whereas transdermal methods—which bypass the liver's first-pass metabolism—did not show the same elevated thrombotic hazards. The investigation included nearly 40,000 women with documented venous thromboembolism, ischemic stroke, or myocardial infarction.
Timeline
The study was published online in The BMJ on September 23, 2026.
HealthDay published an article regarding the findings on October 8, 2026.
Health Landscape
This research continues the long tradition of using large-scale registry data to track the long-term safety profile of hormone replacement therapies. It provides updated context for clinicians comparing oral versus transdermal delivery methods for menopausal patients.
If you are currently taking or considering oral hormone therapy, discuss your personal cardiovascular history and specific dosage with your doctor. You may also want to ask about the potential differences between oral and transdermal formulations regarding your individual risk of stroke.
The takeaway
Hormone therapy delivery methods can significantly affect vascular safety, with oral forms showing higher risks in this study. Monitor for symptoms of stroke or clotting and keep a record of your specific hormone dosage to review during your next checkup.
Further reading
For more on managing vascular health and risk factors, visit our Stroke section.
Live Poll
Does this study make you less confident in the safety of your current hormone therapy?
